Kerry Group: The Shrinking Company That Grows By Margin

Article Thesis

Kerry Group plc (KRYAY), the Irish business-to-business taste-and-nutrition company, used its October 7 investor day to put a number on its medium-term plan: an EBITDA margin of 20-21% by 2030, up from 17.9% in 2025, alongside continued high-single-digit-plus constant-currency EPS growth. I read those targets as the forward proof of a strategy Kerry has pursued for years - deliberately making itself smaller, selling off its lower-margin consumer-foods and dairy businesses so that it now grows earnings mostly through margin expansion and buybacks rather than by selling more. At roughly 18.5x trailing adjusted earnings for that growth, I think the stock is fairly valued: an excellent, defensible business at a full price, worth understanding but not a bargain I would rush into at current levels.

My First Article On Kerry

Kerry sits outside the tech, chip, and energy names I usually cover, and I have not written about it before. I decided to dig in because the economics behind those investor-day targets are unusual and worth explaining, even though the verdict on the price lands closer to "fair" than "cheap."

The Investor Day's Target

At its investor day on October 7, 2026 at its technology and innovation center in Beloit, Wisconsin, Kerry laid out the shape of its business to 2030. The headline is a 20-21% EBITDA margin target, supported by high-single-digit-plus constant-currency EPS growth and 3-5% annual volume growth. The company points to a specialty-ingredients market it sizes at around €87 billion and expects to exceed €100 billion over the next five to ten years, built on more than €3 billion of research and development over the past decade.

That target only means what the numbers behind it allow, so before judging the price we need to see how this company grew itself into it.

A Company That Shrank Its Way To Higher Margins

The first thing to grasp is that Kerry deliberately got smaller. Group revenue fell from €8.02 billion in 2023 to €6,758 million in 2025. That is not a struggling business - it is the result of management selling off lower-margin consumer-foods and dairy operations to leave what it describes as a pure-play business-to-business taste and nutrition company. A falling top line and a rising profit margin appear in the same report for the same reason.

That reshaping is the key to the whole story. Kerry is the company behind the flavors, tastes, and nutritional ingredients that food and beverage brands buy to differentiate their products. Once customers build a product around a Kerry formulation, they are largely locked in, which is exactly the kind of sticky, pricing-power business I like. Kerry competes for that formulation work against the other big flavor-and-ingredient houses, led by Givaudan, with IFF and Symrise close behind.

Where The Growth Actually Comes From

In its full-year 2025 results Kerry reported revenue of €6,758 million, EBITDA of €1,208 million, and an EBITDA margin of 17.9%, up from 17.1% the year before. Adjusted EPS has climbed from 430.1 cents in 2023 to 467.5 cents in 2024 to 481.5 cents in 2025, with constant-currency adjusted EPS growth of 7.5% for the year - landing in the upper half of the company's own 7-11% guidance.

Here is the mechanism, and I think it explains everything. Volume grew 3% in 2025. If Kerry only grew by selling more, EPS would grow roughly in line with that. Instead it grew 7.5% in constant currency. The difference is operating leverage: a small volume gain on in-place manufacturing, a margin that is expanding, and a buyback taking out shares. That is the whole thesis in one line - Kerry compounds at roughly double its volume growth because margin does most of the work.

The investor-day targets confirm the runway rather than mark a change. Since 2021 Kerry has expanded its EBITDA margin by 320 basis points. At 17.9% today, reaching 20-21% by 2030 means roughly another 200 to 300 basis points over a longer window - a real but noticeably slower pace than the expansion it has already delivered. The easy part of the journey is behind it.

The Halfway Check

The half-year numbers released in July 2026 show the engine working under an awkward top line. Revenue fell 3.7% to €3.34 billion while volume rose 3.3% - the gap is currency and pricing, not demand. Reported net profit fell to €282.6 million from €303.1 million, which looks like stagnation; the adjusted profit and the 7.9% constant-currency adjusted EPS growth tell the real story. Kerry maintained its full-year guidance rather than trimming it, and on top of the organic compounding it is returning capital: a €300 million buyback has been cancelling shares, bringing the count down to roughly 157.7 million.

Is 18.5x Fair?

Let's put a price on it. Shares trade around €89 at the time of writing. Against trailing adjusted EPS of €4.815, that is roughly 18.5x earnings. The market is paying that multiple for high-single-digit constant-currency EPS growth, a credible margin runway to 2030, a defensible sticky customer base, and a share count that is shrinking.

I do not think that multiple is crazy, and I do not think it is cheap. For a stable, defensive compounder in food ingredients this is a reasonable price - the growth the multiple buys is real and supported by forward targets, which is more than many stocks can say. But there is not a wide margin of safety. Consider what could defeat the thesis: the easy margin expansion is already banked, and if volume stalls or reformulation pressure builds - think GLP-1 drugs changing how much people eat and the health-led rethink of packaged food that follows - then 18.5x leaves little room for disappointment. Some investors may decide that the steady, recession-resistant compounding justifies paying up; I would rather own it at a lower multiple or once the 20-21% path is further de-risked.

Takeaway

Kerry Group is the kind of business the thesis likes on its operating merits: a sticky, pricing-powerful franchise that grows earnings at a healthy clip despite selling barely more, and that returns cash to shareholders along the way. The investor day is a green light to understand that business - a margin target tells you how the machine is meant to run, not what the stock should cost. At 18.5x adjusted earnings I think the fair value is already largely paid for, so my take is that this is a quality company worth watching, not a stock to chase. The specific risk to monitor is the margin runway itself: the next 200 to 300 basis points are harder than the 320 already delivered, and that is exactly where the expected EPS growth would come from if volume stays modest.